Clinical Trial

Baxdrostat and Ventricular Remodeling

Study acronym: BaxREMODEL
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this trial is to learn whether adding the blood pressure medication baxdrostat (Baxfendy) to standard-of-care medical therapies will beneficially change the heart structure and function of adults who have high blood pressure, thickened left heart walls, and are at risk for heart or kidney disease. To determine if baxdrostat improves heart structure and function, the participants will: * take a baxdrostat or a placebo (a look-alike tablet that contains no drug) tablet once a day for 12 months * undergo a safe and non-invasive cardiac magnetic resonance imaging scan (to measure heart mass, stiffness and function) at the beginning of the study and 12 months later * visit the clinic for checkups and blood or urine tests 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months after taking the first tablet
Trial Details
NCT Number NCT07655362
Lead Sponsor Subodh Verma
Collaborators: AstraZeneca
Conditions Cardiac Remodeling
Enrollment 286 participants
Start Date 2026-06-30
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-17